MYOM2 and plasmacytoma: A pooled analysis of 148 patients with a median of five prior lines of therapy, including 86.5% double-refractory to a PI and an IMiD from these two trials demonstrated an overall response rate (ORR) of 31.1%, including very good partial responses (VGPR, defined as > 90% reduction in serum myeloma protein (M-protein) with urine M-protein level < 100 mg/24 h) in 13 patients, and 4 complete responses (CR, defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow).43